title: Evaluation of primary and secondary responses to a T-cell-dependent antigen, keyhole limpet hemocyanin, in rats.
abstract: To develop a rat T-cell-dependent antibody response (TDAR) model evaluating both primary and secondary antibody responses, keyhole limpet hemocyanin (KLH) was used to immunize rats twice during a 14-day course of study, a pattern closely linked to that of a short-term general toxicity study. Female rats of four representative strains (e.g., Sprague-Dawley, Wistar, Fischer, and Lewis) were immunized twice with intravenous administrations of KLH (300 µg/rat) on Days 5 and 9 during a 14-day treatment regimen with cyclophosphamide (CPA) at 1, 3, or 6 mg/kg/day. The primary and secondary immunizations of KLH markedly elevated serum anti-KLH IgM and IgG levels in all strains on Days 9 and 15. Remarkable higher levels of anti-KLH IgG (≈ 1000 µg/ml) were noted in all strains, which were more than 4-times compared with those of anti-KLH IgM levels at Day 9, indicating that predominant IgG reactions were induced by the dual immunizations. A large inter-individual variability in KLH-specific IgM and IgG production was observed in all strains. However, levels of the KLH-specific antibodies were considered sufficient for the evaluation, even in Sprague-Dawley and Wistar rats reported as strains with a wide range of variability since immunosuppression of CPA on responses in both anti-KLH IgM and IgG were observed in all strains to the same extent. In addition, the sensitivity of the KLH-ELISA assay system detecting the immunosuppressive effects of CPA was comparable to other assay systems with PFC assay or ELISA using SRBC. The results here demonstrated that these experimental designs could provide valuable information about the influence on both the primary and secondary humoral immune responses in rats when exposed to potential immunomodulatory drugs. Furthermore, the design of the presented TDAR study would support comprehensive evaluation together with the outcome of the conventional general toxicity study.
authors.affiliation: Medicinal Safety Research Laboratories, Daiichi Sankyo Co., Ltd., Shizuoka 437-0065, Japan. kawai.ryota.jn@daiichisankyo.co.jp
authors.forename: Ryota
authors.initials: R
authors.lastname: Kawai
authors.forename: Shiho
authors.initials: S
authors.lastname: Ito
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Aida
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Hattori
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Kimura
authors.forename: Tadashi
authors.initials: T
authors.lastname: Furukawa
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Mori
authors.forename: Atsushi
authors.initials: A
authors.lastname: Sanbuissho
authors.forename: Teruo
authors.initials: T
authors.lastname: Kawada
mesh_terms: D000818:Animals; D000917:Antibody Formation; D005260:Female; D006433:Hemocyanins / Q000276:immunology*; D007117:Immunization, Secondary; D007156:Immunologic Memory; D008213:Lymphocyte Activation; D051381:Rats; D011916:Rats, Inbred F344; D011917:Rats, Inbred Lew; D017207:Rats, Sprague-Dawley; D017208:Rats, Wistar; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology*
chemical_list: D006433:Hemocyanins; C032808:keyhole-limpet hemocyanin